Tozinameran

Development status

1. First COVID-19 vaccine approved worldwide
2. First-in-class lipid nanoparticle vaccine
3. Emergency use/conditional marketing authorizations granted in multiple countries
4. Phase 1 clinical trial (sublicensed to Shanghai Fosun Pharmaceutical [Group] Co Ltd) underway in Mainland China
5. Phase 3 clinical trials underway in Argentina, Brazil, South Africa and Turkey
   
6. Japan PMDA reviewing an application for emergency use

Emergency use
authorizations granted in:

Drugs to Watch - Tozinarmeran

Distribution

The vaccine is well-tolerated, is easily administered.

It has a reported 95% efficacy when administered per protocol, but it requires ultra-cold chain storage.